---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064435"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:44:03.260444+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics Q1 2025 net loss $136M; CTX310 Phase 1 shows up to 82% TG reduction

## Summary
- Net loss of $136.0M in Q1 2025, compared to $116.6M in Q1 2024; cash & equivalents $1.86B.
- CTX310 Phase 1 data: dose-dependent reductions in LDL (up to 81%) and TG (up to 82%) with well-tolerated safety.
- CASGEVY: >65 authorized treatment centers activated; ~90 patients with first cell collection; new initiations to grow in 2025.
- R&D expenses $72.5M, G&A $19.3M; collaboration expense net $57.5M (driven by CASGEVY and in vivo HSC editing).
- CTX320 (Lp(a)) dose escalation ongoing with update expected Q2 2025; CTX112/CTX131 CAR T updates mid-2025.

## SEC filing metadata
- accession: 0000950170-25-064435
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017025064435/0000950170-25-064435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017025064435/crsp-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064435
- JSON: https://secwatch.observer/filing/0000950170-25-064435.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.